# Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)

Study · id `cardio:ct-nct03888066` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03888066](<https://clinicaltrials.gov/study/NCT03888066>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03888066

Browse, organ or system: Heart; Blood vessels; Kidneys  
Browse, condition area: High blood pressure; Heart failure; Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1195 participants.

## Technical summary

Registry record NCT03888066. Randomized; quadruple masking; primary purpose prevention. Start 2019-04-24 (actual); primary completion 2021-09-02 (actual). Results posted on 2023-02-24.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 1195 participants (enrolled count; ClinicalTrials.gov record NCT03888066, source copy `cardio:ctgov-nct03888066-2023-02-24`, retrieved 2026-10-26)
- Started: 2019-04-24 (actual) (ClinicalTrials.gov record NCT03888066, source copy `cardio:ctgov-nct03888066-2023-02-24`, retrieved 2026-10-26)
- Primary completion: 2021-09-02 (actual) (ClinicalTrials.gov record NCT03888066, source copy `cardio:ctgov-nct03888066-2023-02-24`, retrieved 2026-10-26)
- Completion: 2021-09-02 (actual) (ClinicalTrials.gov record NCT03888066, source copy `cardio:ctgov-nct03888066-2023-02-24`, retrieved 2026-10-26)
- Results first posted: 2023-02-24 (ClinicalTrials.gov record NCT03888066, source copy `cardio:ctgov-nct03888066-2023-02-24`, retrieved 2026-10-26)
- Countries: United States; Argentina; Belgium; Brazil; Bulgaria; Canada; Czechia; France; Georgia; Germany; Hungary; Israel; Italy; Mexico; Netherlands; Poland; Russia; Serbia; Spain; Ukraine; United Kingdom (ClinicalTrials.gov record NCT03888066, source copy `cardio:ctgov-nct03888066-2023-02-24`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03888066-2023-02-24`, retrieved 2026-10-26)

## The registry's words

- Brief title: Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)
- Acronym: DIAMOND
- Condition: Hyperkalemia
- Intervention (Drug): Patiromer
- Intervention (Drug): Placebos
- Lead sponsor: Vifor Pharma, Inc.
- Lead sponsor class: INDUSTRY
- Collaborator: Syneos Health
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as a collaborator: Syneos Health (`cardio:org-syneos-health`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial (`cardio:pubmed-35900838`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Patiromer-Facilitated Renin-Angiotensin-Aldosterone System Inhibitor Utilization in Patients with Heart Failure with or without Comorbid Chronic Kidney Disease: Subgroup Analysis of DIAMOND Randomized Trial (`cardio:pubmed-39159624`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Patiromer for Heart Failure Medication Optimization in Patients With Current or Past Hyperkalemia: DIAMOND Subanalysis (`cardio:pubmed-39340493`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 6f9c79fede9396559aa365dd3cc72e163dc9dc500f4f50b606a7d06ddea1a3e6
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
